Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alvogen is first with Revlimid rival in EU

Executive Summary

Alvogen is claiming the first approvals in “several European countries” for its generic version of Celgene’s Revlimid (lenalidomide) capsules, after its Lotus Pharmaceuticals affiliate “successfully concluded multiple registration procedures” for the oncology drug. Lotus’ lenalidomide has been approved in European markets in seven strengths: 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg and 25mg capsules.

You may also be interested in...



Accord’s UK Lenalidomide Launch Kicks Off A Year Of Revlimid Competition

Accord has confirmed the launch of a generic lenalidomide rival to Revlimid in the UK. The launch leads off a year that is expected to see the BMS blockbuster also face significant competition elsewhere in Europe and the US.

Alvogen Claims Lead On Lenalidomide In Europe

Alvogen is claiming the first European launch of a generic rival to Revlimid, rolling out the oncology drug in several central and eastern European markets. Meanwhile, IPR challenges to three Revlimid patents in the US have been denied.

JB Chemicals Acquires Several Sanzyme Brands

JB Chemicals has purchased a number of leading brands from Sanzyme, which it plans to scale up and institutionalize within India. The transaction, worth over $80m, is expected to close within the next two weeks.

Topics

UsernamePublicRestriction

Register

GB000720

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel